{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-22-003581","form_type":"8-K","ticker":"PGEN","cik":"0001356090","company_name":"PRECIGEN, INC.","filed_at":"2022-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.095455+00:00","generated_at":"2026-06-27T02:52:37.728717+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Precigen Q4 net loss $25M, FY loss $96.8M; $163.7M cash; clinical progress","bullets":["Q4 net loss from continuing ops $25.0M ($0.13/sh) vs $39.7M ($0.22/sh) year ago; full-year net loss $96.8M ($0.49/sh) vs $103.8M.","Cash, cash equivalents and investments totaled $163.7M as of Dec 31, 2021; net cash used in ops $55.8M in 2021, down from $77.0M in 2020.","January 2021 public offering of 17.25M shares raised gross proceeds of ~$129.4M; cash expected to fund operations well into 2023.","Clinical milestones: completed enrollment in PRGN-3006 AML, PRGN-3005 ovarian, and PRGN-2012 RRP studies; IND clearances for PRGN-3007 and PRGN-2012.","R&D expenses up 20% for the year; SG&A down 19%; non-core businesses (Trans Ova, Exemplar) increased revenues and profitability."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-22-003581","json":"https://secwatch.observer/filing/0000950103-22-003581.json","markdown":"https://secwatch.observer/filing/0000950103-22-003581.md","text":"https://secwatch.observer/filing/0000950103-22-003581.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356090/000095010322003581/0000950103-22-003581-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356090/000095010322003581/dp168191_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T02:52:37.728717+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}